Publications by authors named "Peter A Ljubenkov"

Claim this Profile
B
Blood-based Alzheimer's disease biomarkers in a behavioral neurology clinic: Real-world implementation, clinical utility, and diagnostic performance.
Igor Prufer Q C Araujo, Tara Ellingson, Nicholas U Schwartz, Connor D Dietz, Gautam Tammewar, Peter A Ljubenkov

Alzheimers Dement· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma lipidome dysregulation in frontotemporal dementia reveals shared, genotype-specific, and severity-linked alterations.
Yohannes A Ambaw, Peter A Ljubenkov, Shubham Singh, Abdi Hamed, Sebastian Boland

Alzheimers Dement· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes of a Cerebral Cavernous Malformation Associated With Lecanemab Therapy in a Patient With Alzheimer Disease.
Nicholas U Schwartz, Connor D Dietz, Igor Prufer Araújo, Javier E Villanueva-Meyer, Winston Chiong, Peter A Ljubenkov

Neurol Clin Pract· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration.
Rowan Saloner, Adam M Staffaroni, Eric B Dammer, Erik C B Johnson, Emily W Paolillo, Peter A Ljubenkov

Nat Aging· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration.
Rowan Saloner, Adam M Staffaroni, Eric B Dammer, Erik C B Johnson, Emily W Paolillo, Peter A Ljubenkov

Nat Aging· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab.
Lawren VandeVrede, Renaud La Joie, Sheena Horiki, Nidhi S Mundada, Mary Koestler, Peter A Ljubenkov

Acta Neuropathol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and neuropathological associations of plasma Aβ/Aβ, p-tau217 and neurofilament light in sporadic frontotemporal dementia spectrum disorders.
Binita Rajbanshi, Igor Prufer Q C Araujo, Lawren VandeVrede, Peter A Ljubenkov, Adam M Staffaroni

Alzheimers Dement (Amst)· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CSF Proteomics in Patients With Progressive Supranuclear Palsy.
Amy Wise, Jingyao Li, Mai Yamakawa, Joseph Loureiro, Brant Peterson, Peter A Ljubenkov

Neurology· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinicopathological correlation of cerebrospinal fluid alpha-synuclein seed amplification assay in a behavioral neurology autopsy cohort.
Niyatee Samudra, D Luke Fischer, Steven Lenio, Argentina Lario Lago, Peter A Ljubenkov

Alzheimers Dement· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab.
Lawren VandeVrede, Renaud La Joie, Sheena Horiki, Nidhi S Mundada, Mary Koestler, Peter A Ljubenkov

Acta Neuropathol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma inflammation for predicting phenotypic conversion and clinical progression of autosomal dominant frontotemporal lobar degeneration.
Breton M Asken, Peter A Ljubenkov, Adam M Staffaroni, Kaitlin B Casaletto, Lawren Vandevrede

J Neurol Neurosurg Psychiatry· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Silencing tau to treat early Alzheimer's disease.
Peter A Ljubenkov, Gil D Rabinovici

Nat Med· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal Syndrome.
Lawren VandeVrede, Renaud La Joie, Elisabeth H Thijssen, Breton M Asken, Stephanie A Vento, Peter A Ljubenkov

JAMA Neurol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sensitivity of the Social Behavior Observer Checklist to Early Symptoms of Patients With Frontotemporal Dementia.
Gianina Toller, Yann Cobigo, Peter A Ljubenkov, Brian S Appleby, Bradford C Dickerson

Neurology· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case Report: Novel Variant in a Patient With Behavioral Variant Frontotemporal Dementia Syndrome With Prodromal Repetitive Scratching Behavior.
Adit Friedberg, Eliana Marisa Ramos, Zhongan Yang, Luke W Bonham, Jennifer S Yokoyama, Peter A Ljubenkov

Front Neurol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency: A Randomized Clinical Trial.
Peter A Ljubenkov, Lauren Edwards, Leonardo Iaccarino, Renaud La Joie, Julio C Rojas

JAMA Netw Open· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care.
Brent Bluett, Alexander Y Pantelyat, Irene Litvan, Farwa Ali, Diana Apetauerova, Peter Alexander Ljubenkov

Front Neurol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration.
Julio C Rojas, Ping Wang, Adam M Staffaroni, Carolin Heller, Yann Cobigo, Peter A Ljubenkov

Neurology· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FTLD Treatment: Current Practice and Future Possibilities.
Peter A Ljubenkov, Adam L Boxer

Adv Exp Med Biol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Four-Repeat Tauopathies: Current Management and Future Treatments.
Lawren VandeVrede, Peter A Ljubenkov, Julio C Rojas, Ariane E Welch, Adam L Boxer

Neurotherapeutics· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Symptomatic amyloid-related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab.
Lawren VandeVrede, Daniel M Gibbs, Mary Koestler, Renaud La Joie, Peter A Ljubenkov

Alzheimers Dement (Amst)· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open-Label Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear Palsy.
Lawren VandeVrede, Marian L Dale, Scott Fields, Megan Frank, Emma Hare, Peter A Ljubenkov

Mov Disord Clin Pract· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Cognitive and Behavioral Features Between Adults With Tuberous Sclerosis and Frontotemporal Dementia.
Andy J Liu, Adam M Staffaroni, Julio C Rojas-Martinez, Nicholas T Olney, Carolina Alquezar-Burillo, Peter A Ljubenkov

JAMA Neurol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome: A Randomized Clinical Trial.
Richard M Tsai, Zachary Miller, Mary Koestler, Julio C Rojas, Peter A Ljubenkov

JAMA Neurol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint.
Adam M Staffaroni, Lynn Bajorek, Kaitlin B Casaletto, Yann Cobigo, Sheng-Yang M Goh, Peter A Ljubenkov

Alzheimers Dement· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis